Mackenzie Financial
ITCI

Mackenzie Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mackenzie Financial’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,919
Closed -$337K – 1695
2024
Q2 		$337K Sell
4,919
-2,407
-33% -$167K ﹤0.01% 1120
2024
Q1 		$507K Buy
7,326
+3,289
+81% +$226K ﹤0.01% 1021
2023
Q4 		$289K Buy
+4,037
New +$232K ﹤0.01% 1165
2023
Q3 		– Sell
-7,589
Closed -$475K – 1612
2023
Q2 		$475K Buy
7,589
+1,946
+34% +$121K ﹤0.01% 1034
2023
Q1 		$306K Hold
5,643
– – ﹤0.01% 1177
2022
Q4 		$299K Sell
5,643
-298
-5% -$14.9K ﹤0.01% 1092
2022
Q3 		$276K Sell
5,941
-50,989
-90% -$2.66M ﹤0.01% 1123
2022
Q2 		$3.25M Buy
56,930
+52,389
+1,154% +$2.97M 0.01% 618
2022
Q1 		$278K Buy
4,541
+700
+18% +$36.4K ﹤0.01% 1153
2021
Q4 		$201K Buy
+3,841
New +$161K ﹤0.01% 1337

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mackenzie Financial's ITCI Position: Q3 2024 in Review

Mackenzie Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 4,919 shares — an estimated $337K sold.

Mackenzie Financial first reported a position in ITCI in Q4 2021 and held it in 10 quarters. The position peaked at $3.25M in Q2 2022. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Mackenzie Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Mackenzie Financial sold 4,919 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $337K.
  • Mackenzie Financial first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 10 quarters.
  • Mackenzie Financial's Intra-Cellular Therapies Inc. position peaked at $3.25M in Q2 2022.
  • 354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Mackenzie Financial's 13F filing for Q3 2024, filed 13 Nov 2024.